Abstracts tagged "autoimmune diseases"

Abstract Number: 2224 • ACR Convergence 2022
Genes Causative of Primary Immunodeficiency Are Risk Factors for and Over-expressed in Systemic Lupus Erythematosus
Haley Davis¹, Adam Labonte¹, Katherine Owen², Erika Hubbard¹, Jessica Kain¹, Brian Kegerreis¹, Prathyusha Bachali³, Amrie Grammer⁴ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²RILITE, Crozet, VA, ³AMPEL BioSolutions, Redmond, WA, ⁴AMPEL LLC, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) is a polygenic autoimmune disease whose specific causes are incompletely understood and for which there exists no single comprehensive diagnostic…
Abstract Number: 0083 • ACR Convergence 2022
COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network
Amy Mudano¹, Fenglong Xie¹, Patrick Stewart², Lesley Jackson³, Maria Danila³, Kelly Gavigan⁴, William Benjamin Nowell⁵, Shilpa Venkatachalam⁶ and Jeffrey Curtis⁷, ¹Illumination Health, Hoover, AL, ²Bendcare, Boca Raton, FL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Global Healthy Living Foundation, New York, NY, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Sub-optimal COVID-19 vaccine uptake by patients with autoimmune conditions is an area of concern to many rheumatologists and other providers. It is important to…
Abstract Number: 0202 • ACR Convergence 2022
Learning Needs Assessment for Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Maria A. Lopez-Olivo¹, Johncy Kachira², Maryam Buni³, Sang Taek Kim⁴, Huifang Lu⁴, Gabrielle Duhon⁴, Juan Ruiz⁴, Clifton O. Bingham III⁵, Cassandra Calabrese⁶, Robert J. volk⁴ and Maria Suarez-Almazor⁷, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Texas, TX, ³MD Anderson Cancer Center, Bellaire, TX, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵Johns Hopkins University, Baltimore, MD, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷MD Anderson Cancer Center, Houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) have been extremely successful in the treatment of various malignancies. Patients with pre-existing autoimmune disorders and cancer are at risk…
Abstract Number: 0578 • ACR Convergence 2022
Interleukin-6 Trans-Signaling Induces Synovial Fibroblast Invasiveness by Utilizing Ets2 Protein
Anil Singh, Paul Panipinto, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease with a complex interplay of synovial cells and soluble factors that create the signatures of chronic inflammation…
Abstract Number: 0669 • ACR Convergence 2022
Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus
Thomas Li¹, Ethan Seltzer¹, Victoria Zyulina¹, Keila Veiga², Noa Schwartz³, Yurii Chinenov¹, David Oliver¹, Jose Lora⁴, Ali Jabbari⁵, Yong Liu¹, Hafsa Munir¹, William Shipman¹, Marvin Sandoval¹, Isabel Sollohub¹, william ambler¹, Bikash Mishra⁴, sarah taber¹, karen onel¹, Mehdi Rashighi⁶, james krueger⁷, Niroshana Anandasabapathy⁴, Carl Blobel¹ and theresa Lu¹, ¹Hospital for Special Surgery, New York, NY, ²Maria Fareri Children's Hospital, New York, NY, ³Albert Einstein College of Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵University of Iowa, Iowa City, IA, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷Rockefeller University, New York, NY
Background/Purpose: Photosensitivity is a hallmark symptom of lupus erythematosus (LE), in which patients develop inflammatory skin lesions in response to ultraviolet radiation (UVR). In examining…
Abstract Number: 0750 • ACR Convergence 2022
Quality Improvement Project to Increase the Rate of Vaccination with Pneumococcal Vaccines (PCV13 prime-PPSV23 Boost Strategy) Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Within Nationwide Health Organization
Victoria Furer, Hagit Sarbagil-Maman and Ori Elkayam, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are susceptible for pneumococcal disease. Two vaccines against S. pneumoniae are currently recommended for use: a 23-valent…
Abstract Number: 0805 • ACR Convergence 2022
Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
Quentin AMIC-DESVAUD¹, Olivier MAILLARD², Sylvia IACOBELLI³, Thomas BARDIN⁴ and Yves-Marie DUCROT⁵, ¹Province des îles Loyauté, Lifou, New Caledonia, ²Centre Hospitalier Universitaire de la Reunion, Saint-Denis, France, ³Centre Hospitalier Universitaire, Saint Dénis de la Réunion, France, ⁴Université de Paris, Paris, France, ⁵Province des îles Loyauté, We, Lifou Island, New Caledonia
Background/Purpose: Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD) remain major public health problems in the South Pacific. Triggering by group A beta hemolytic…
Abstract Number: 1049 • ACR Convergence 2022
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Hilde Jenssen Bjørkekjær¹, cosimo bruni², PATRICIA E CARREIRA³, Paolo Airò⁴, CARMEN PILAR SIMEON⁵, Marie-Elise Truchetet⁶, Alessandro Giollo⁷, Alexandra Balbir-Gurman⁸, Mickaël MARTIN⁹, Chris Denton¹⁰, Armando Gabrielli¹¹, Håvard Fretheim¹², Imon Barua¹², Helle Bitter¹³, Øyvind Midtvedt¹², Kaspar Broch¹⁴, Arne Andreassen¹², Yoshiya Tanaka¹⁵, Gabriela Riemekasten¹⁶, Ulf Müller-Ladner¹⁷, Marco Matucci-Cerinic², Ivan Castellvi¹⁸, Elise Siegert¹⁹, Eric Hachulla²⁰, Oliver Distler²¹ and Anna-Maria Hoffmann-Vold¹², ¹Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, ²University of Florence, Florence, Italy, ³HOSPITAL 12 DE OCTUBRE, Madrid, Spain, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, ⁵Hospital Vall D'Hebron, Barcelona, Spain, ⁶CHU de Bordeaux, Bordeaux, France, ⁷Rheumatology Section, Department of Medicine, University of Verona, Italy, Verona, Italy, ⁸Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel, ⁹Poitiers's Universatory Hospital, Department of Internal Medicine, Poitiers, France, Mignaloux-Beauvoir, France, ¹⁰University College London, London, United Kingdom, ¹¹Università Politecnica delle Marche, Ancona, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Sorlandet sykehus, Kristiansand, Norway, ¹⁴Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, Oslo, Norway, ¹⁵University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ¹⁶University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, ¹⁷JLU Campus KK, Bad Nauheim, Germany, ¹⁸Hospital Universitari de la Santa Creu i Sant Pau, Vilafranca del Pened, Spain, ¹⁹Charité Hospital, Berlin, Germany, ²⁰University of Lille, LILLE, France, ²¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…
Abstract Number: 1217 • ACR Convergence 2022
The Problem of Pain in Rheumatology: Clinical Profiles Associated with Concomitant Diagnoses with Chronic Overlapping Pain Conditions
Titilola Falasinnu¹, Yashaar Chaichian² and Julia Simard³, ¹Stanford School of Medicine, Stanford, CA, ²Stanford University, Stanford, CA, ³Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: The chronification of pain is heterogeneous in rheumatology. Chronic overlapping pain conditions (COPCs) such as fibromyalgia, endometriosis, migraine, and back pain may co-occur with…
Abstract Number: 1455 • ACR Convergence 2022
Immune Thrombocytopenic Purpura and Subsequent Development of Systemic Lupus Erythematosus
Gelsomina Alle¹, Marina Scolnik¹, VALERIA SCAGLIONI¹, John Fredy Jaramillo Gallego¹, Mayra Alejandra Tobar Jaramillo¹, Rodolfo Alvarado¹, Enrique R Soriano² and Javier Eduardo Rosa¹, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study is to assess the incidence of Systemic Lupus Erythematosus (SLE) in a cohort of patients with Immune Thrombocytopenic Purpura…
Abstract Number: 1700 • ACR Convergence 2022
IL-21/STAT3 Pathway Mediated Th2-like Vδ2 T Cells Promote Plasmablasts Differentiation in IgG4-Related Disease
Jieqiong Li¹ and Wen Zhang², ¹Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ²Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To explore the phenotype and role of gamma delta (γδ) T cells in the pathogenesis of IgG4-related disease (IgG4-RD), focusing on the effect on…
Abstract Number: 1985 • ACR Convergence 2022
The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease
Thomas Jonassen¹, Irene Sandholdt², Birgitte Telmer² and Ellen-Margrethe Hauge³, ¹SynAct Pharma, Holte, Denmark, ²CroxxMed, Hørsholm, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammatory activity and the promotion of inflammatory resolution. AP1189 is novel biased…
Abstract Number: 2237 • ACR Convergence 2022
Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods
Rohit Aggarwal¹, Ingrid Lundberg², Yeong-Wook Song³, Aziz Shaibani⁴, Victoria Werth⁵ and Michael Maldonado⁶, ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ³Seoul National University, Seoul, Republic of Korea, ⁴Nerve and Muscle Center of Texas, Houston, TX, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: A 52-week (wk), randomized, placebo (PBO)-controlled phase 3 trial of subcutaneous (SC) abatacept (ABA) and standard of care (SOC) was performed in patients (pts)…
Abstract Number: 0084 • ACR Convergence 2022
Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review
Silke Neusser¹, Anja Neumann¹, Christian Speckemeier¹, Pauline zur NIeden¹, Sarah Schlierenkamp¹, Anke Walendzik¹, Ute Karbach², Ioana Andreica³, Kristina Vaupel⁴, Xenofon Baraliakos⁵ and Uta Kiltz⁴, ¹Essener Forschungsinstitut für Medizinmanagement, Essen, Germany, ²Institute of Medical Sociology, Health Services Research and Rehabilitation Science (IMVR), Cologne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) remain underrepresented in receiving vaccinations despite being disproportionately affected by infectious complications. The aim of our study…
Abstract Number: 0209 • ACR Convergence 2022
Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Thomas Vazquez⁶, Felix Chin⁷, Barbara White⁸ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶FIU Wertheim College of Medicine, Virginia Beach, VA, ⁷University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁸SFJ Pharmaceuticals, Towson, MD
Background/Purpose: Variations of the Investigator Global Assessment (IGA) of overall skin disease have been successfully used as a primary efficacy endpoint in registrational clinical trials…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].